Galera Therapeutics completes acquisition of Nova Pharmaceuticals
31 déc. 2024 07h00 HE
|
Galera Therapeutics
Galera’s development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer. Lead program is...
Galera Announces Board Approval of Complete Liquidation and Dissolution
14 août 2024 07h00 HE
|
Galera Therapeutics
MALVERN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company historically focused on developing a pipeline of novel,...
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
13 mai 2024 07h00 HE
|
Galera Therapeutics
Galera's First Quarter 2024 Earnings Release
Galera Adopts Limited Duration Stockholder Rights Agreement
03 mai 2024 07h00 HE
|
Galera Therapeutics
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the...
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
28 mars 2024 07h00 HE
|
Galera Therapeutics
MALVERN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have...
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
14 nov. 2023 07h00 HE
|
Galera Therapeutics
FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic options to optimize shareholder value MALVERN, Pa., Nov. 14,...
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update
31 oct. 2023 07h00 HE
|
Galera Therapeutics
FDA confirms need for new trial for avasopasem for severe oral mucositis (SOM) GRECO-2 trial did not pass futility analysis; Company will discontinue both GRECO trials Company reviewing potential...
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem
18 sept. 2023 07h00 HE
|
Galera Therapeutics
MALVERN, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
05 sept. 2023 07h00 HE
|
Galera Therapeutics
MALVERN, Pa., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
14 août 2023 07h00 HE
|
Galera Therapeutics
Company received Complete Response Letter from FDA for avasopasem and intends to request Type A meeting with FDA to discuss potential next steps Cash runway extended into Q2 2024 in connection with...